Risk of gastric cancer, gastrointestinal cancers and other cancers: A comparison of treatment with pantoprazole and other proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 1, 2016, Pages 73-82

  Schneider, J L ^a   Kolitsopoulos, F ^b   Corley, D A ^a  

^a DIVISION OF RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONSULTATION; DIGESTIVE SYSTEM CANCER; DRUG EXPOSURE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS CANCER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SENSITIVITY ANALYSIS; SMALL INTESTINE CANCER; STOMACH CANCER; UNITED STATES; ADOLESCENT; CALIFORNIA; DOSE RESPONSE; HELICOBACTER PYLORI; MIDDLE AGED; NEOPLASMS; STOMACH NEOPLASMS; TIME FACTOR; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; CALIFORNIA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84951908316     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13450     Document Type: Article

References (28)

1. Betton GR, Dormer CS, Wells T, et al,. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol 1988; 16: 288-98.
2. Berlin RG,. Omeprazole. Gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci 1991; 36: 129-36.
3. Freston JW,. Omeprazole, hypergas-trinemia, and gastric carcinoid tumors. Ann Intern Med 1994; 121: 232-3.
4. Waldum HL, Sandvik AK, Brenna E, Petersen H,. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698-701.
5. Waldum HL, Sandvik AK, Idle JR,. Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 1998; 114: 1113-5.
6. Qvigstad G, Falkmer S, Westre B, Waldum HL,. Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas"). APMIS 1999; 107: 1085-92.
7. Kidd M, Tang LH, Modlin IM, et al,. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia. Digestion 2000; 62: 143-51.
8. Ho AC, Horton KM, Fishman EK,. Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings. Clin Imaging 2000; 24: 200-3.
9. Henwood M, Clarke PA, Smith AM, Watson SA,. Expression of gastrin in developing gastric adenocarcinoma. Br J Surg 2001; 88: 564-8.
10. Dockray GJ, Varro A, Dimaline R, Wang T,. The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63: 119-39.
11. van Soest EM, van Rossum LG, Dieleman JP, et al,. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966-73.
12. Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT,. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf 2009; 18: 540-4.
13. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT,. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755-60.
14. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD,. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748-54.
15. Bosetti C, Lucenteforte E, Bracci PM, et al,. Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2013; 24: 2903-10.
16. Bradley MC, Murray LJ, Cantwell MM, Hughes CM,. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer 2012; 106: 233-9.
17. Mackenzie IS, Coughtrie MW, MacDonald TM, Wei L,. Antiplatelet drug interactions. J Intern Med 2010; 268: 516-29.
18. Wedemeyer RS, Blume H,. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37: 201-11.
19. Arbel Y, Birati EY, Finkelstein A, et al,. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol 2013; 36: 342-6.
20. Krieger N,. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992; 82: 703-10.
21. Graham DJ, Campen D, Hui R, et al,. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
22. Schatz M, Zeiger RS, Vollmer WM, et al,. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117: 995-1000.
23. El-Serag H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73 e1261.
24. Lundell L., Vieth M., Gibson F., Nagy P., Kahrilas P.J,. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649-63.
25. Attwood SE, Ell C, Galmiche JP, et al,. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015; 41: 1162-74.
26. Poulsen AH, Christensen S, McLaughlin JK, et al,. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 2009; 100: 1503-7.
27. Ahn JS, Eom CS, Jeon CY, Park SM,. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol 2013; 19: 2560-8.
28. Eslami L, Nasseri-Moghaddam S,. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med 2013; 16: 449-58.